



8 June 2023

**Avacta Group plc**

("Avacta" or "the Group" or "the Company")

**Avacta Annual General Meeting and Shareholder Event Detailed Agenda**

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to provide a detailed agenda for the 2023 Annual General Meeting ("AGM") of Shareholders and subsequent Shareholder Event. The AGM will be held on Wednesday, 28 June 2023 at 10.30 a.m. BST at The Royal Society of Medicine, 1 Wimpole Street, Westminster, London W1G 0AE (the "Venue").

**10:15** Arrivals with coffee and biscuits.

**10:30** Formal AGM Business and Voting on Resolutions chaired by Eliot Forster.

**11:00** Business Update and Q&A: CEO Alastair Smith.

**12:00** Buffet Lunch and poster session with the opportunity to meet the Group's Senior Leadership.

- AVA6000 Poster
- AVA3996 Poster
- Affimer Therapeutics Poster
- Affimer Diagnostics Poster
- Launch Diagnostics Stand

**13:00** AVA6000 Review of Public Domain Clinical Data.

**13:20** Diagnostics Division Strategy with Q&A: Alastair Smith.

**13:40** Closing comments and final Q&A: Alastair Smith.

**14:00** Event ends.

No new material information will be disclosed during the meeting.

The Business Update (11:00-12:00) will be simultaneously streamed live on the Investor Meet Company ("IMC") platform. Investors who already follow Avacta on IMC will automatically be invited to join the live stream. Investors who do not have an IMC account can sign up for free at <https://www.investormeetcompany.com/avacta-group-plc/register-investor> and then click "Add to meet" Avacta Group in order to receive an invitation.

The Venue has a capacity of approximately 140 people. Shareholders who wish to attend the AGM in person are requested to register by emailing FTI Consulting at [avacta.ls@fticonsulting.com](mailto:avacta.ls@fticonsulting.com) by 10:30 a.m. BST on 27 June 2023.

**- ENDS -**

**For further information from Avacta Group plc, please contact:**

**Avacta Group plc**  
Alastair Smith, Chief Executive Officer  
Tony Gardiner, Chief Financial Officer  
Michael Vinegrad, Group Communications Director

Tel: +44 (0) 1904 21 7070  
[www.avacta.com](http://www.avacta.com)

**Stifel Nicolaus Europe Limited (Nomad and Broker)**  
Nicholas Moore / Nick Adams / Samira Essebiyea  
/ Nick Harland / Dhiren Suares / William Palmer-Brown

Tel: +44 (0) 207 710 7600  
[www.stifel.com](http://www.stifel.com)

**FTI Consulting (Financial Media and IR)**  
Simon Conway / Alex Shaw

Tel: +44(0) 203 727 1000  
[Avacta.LS@fticonsulting.com](mailto:Avacta.LS@fticonsulting.com)

**Zyme Communications (Trade and Regional Media)**  
Lily Jeffery

Tel: +44 (0)7891 477 378  
[lily.jeffery@zymecommunications.com](mailto:lily.jeffery@zymecommunications.com)

**About Avacta Group plc** - <https://www.avacta.com>

Avacta Group plc is a life sciences company working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics. Operating through two divisions, Diagnostics and Therapeutics, the Group's mission is to provide professionals and consumers with solutions that improve healthcare, fitness and well-being.

Avacta's *Therapeutics Division*, a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer<sup>®</sup> immunotherapies and pre|CISION<sup>™</sup> tumour targeted chemotherapies. This approach is designed to address the lack of a durable response to current cancer immunotherapies experienced by most patients and reduce the severe systemic toxicities caused by chemotherapies. There are five programmes in the pipeline as well as several global research collaborations and licensing partnerships. Avacta's lead programme, AVA6000, is a pre|CISION<sup>™</sup> tumour-targeted form of the established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in patients with locally advanced or metastatic selected solid tumours.

The Affimer<sup>®</sup> platform is an alternative to antibodies that has been designed to address many of the drawbacks of antibodies which, despite their shortcomings, currently dominate the immuno-diagnostics and immuno-therapeutics markets.

The pre|CISION<sup>™</sup> tumour targeting platform can be used to modify a chemotherapy in order to selectively release the active drug in tumour tissue thereby reducing the systemic exposure that causes damage to healthy tissues. pre|CISION<sup>™</sup> modified chemotherapies are designed to reduce the side effects and improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.

Avacta's *Diagnostics Division* develops and supplies a broad range of in-vitro diagnostic (IVD) solutions. The Division is growing rapidly through an M&A strategy to deliver a global scale IVD business providing market leading solutions for healthcare professionals and consumers to inform treatment and monitor health and well-being. In October 2022, Avacta acquired Launch Diagnostics which serves the hospital pathology laboratory market in the UK and Europe. In May 2023, Avacta acquired Coris Bioconcept a Belgium based lateral flow test developer and manufacturer adding a broad range of marketed professional-use rapid tests into the *Diagnostics Division*. Avacta Diagnostic's research and development centre in Wetherby, UK uses its proprietary Affimer<sup>®</sup> platform to differentiate immunodiagnostic products to provide marketing leading performance.

To register for news alerts by email go to [www.avacta.com/investor-news-email-alerts](http://www.avacta.com/investor-news-email-alerts)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFZGGVNNNGFZM